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Summary. Clinical trials in vulnerable populations are extremely difficult to conduct. A sequen-
tial phase I–II trial aimed at finding the appropriate dose of levetiracetam for treating neonatal
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seizures was planned with a maximum sample size of 50 newborns. Three primary outcomes
are considered: efficacy and two types of toxicity that occur at the same time but are measured
at different time points. In the case of failure, physicians could add a second agent as a rescue
medication.The primary outcomes were modelled via a logistic model for efficacy and a weighted
likelihood with pseudo-outcomes for the two toxicities taking into account the dependences
under Bayesian inference. Simulations were conducted to assess the design properties.
Keywords: Efficacy; Newborns; Phase I–II; Time to event; Toxicity constraints
1. Introduction
The aim of early phase dose ﬁnding trials is to obtain reliable information on a drug’s safety,
tolerability, pharmacokinetics, mechanism of action and trends regarding efﬁcacy. Usually,
these trials are performed on healthy adult volunteers, except when the drug is very toxic as
in oncology. In paediatrics clinical trials, the practice of including healthy infants in phase I
studies only for safety assessment is generally considered unethical. Drugs or procedures are
often directly evaluated for efﬁcacy in clinical trials (Gill, 2004) with certain safety stopping
rules to protect infants from toxic drugs or procedures. Such trials are often known as phase
I–II trials (Yuan et al., 2016), where efﬁcacy and toxicity are studied simultaneously. Many dose
ﬁnding designs have been proposed for adults in the oncology setting (Zohar and O’Quigley,
2006; Yuan et al., 2016), but only a few of themwere speciﬁcally developed for paediatrics or for
other indications than oncology. Thall et al. (2014) proposed a dose ﬁndingmethod for neonates
with respiratory distress syndrome based on three clinical outcomes.
Conducting early phase clinical trials in neonates is challenging. Correct dosing is obstructed
by the fast physiological changes that occur in neonates at this stage of development (Coppini
et al., 2016). Neonates are not very small adults or ‘young’ children, but they have a completely
differentmetabolism fromadults and older children. Furthermore, there is no direct relationship
as a function of body surface or allometry that links the pharmacokinetics and pharmacody-
namics variables, such as the clearance or the constant of absorption related to the drug (Petit
et al., 2016a, b). As a result, the deﬁnitions of efﬁcacy and toxicity end points for neonates are
often substantially different from those for adults or children (2 years old or more). In addition,
selecting proper efﬁcacy and toxicity end points and measuring them in neonates are more difﬁ-
cult and subjective (Denne, 2012; Thall et al., 2014; Coppini et al., 2016). For example, because
neurological damage cannot be measured before 1 or 2 years after birth, surrogate end points,
such as anaphylactic shock or long duration apnoea, must be used as a measure of neurological
damage in neonates. In our motivating trial, one potential adverse event (AE) that is caused by
the treatment is hearing loss. Such an AE is easy to capture in realtime for adults but difﬁcult
to measure in neonates. A speciﬁc hearing test must be scheduled and performed to diagnose it.
Because of those difﬁculties coupled with the many ethical challenges, dose ﬁnding in neonates
has been largely done in an ad hoc way without formal statistical modelling and considerations.
Usual challenges in these kind of trials include
(a) the deﬁnition of multiple types of toxicity, that can be observed or measured at different
times after the treatment and can be correlated,
(b) the addition of another rescue drug or treatment, and sometimes it could be unclear
whether the resulting toxicity is due to the test treatment or to the additional one and
(c) the small target of probability of an AE which is accepted for the treatment.
These characteristics are not only limited to clinical trials in neonates or paediatrics, but also
in rare disease in adults, for example. In what follows, we address these challenges by stating a
motivating trial in newborns.
In this paper, we propose a Bayesian phase I–II design for the ‘Levetiracetam treatment of
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neonatal seizures: safety and efﬁcacy phase II study’ (called the ‘LEVNEONAT’ trial; regis-
tration number NCT 02229123 at www.ClinicalTrials.gov) to ﬁnd the optimal dose of
levetiracetam for treating seizures in neonates. As detailed later, this trial has some challenges
that are associated with treating neonates. For example, hearing loss cannot be measured in
realtime and is only ascertained at day 30, and a new drug may be added during the course of
the treatment if clinicians believe that levetiracetam alone is not adequately effective to reduce
seizure. To handle these challenges, we model three end points (one efﬁcacy and two toxicity
end points) and utilize a pseudolikelihood approach for inference. On the basis of accumulating
data, we continuously update the model estimates and adaptively assign doses to new patients.
The remainder of this paper is organized as follows. In Section 2, we describe our motivating
clinical trial and some challenges. In Section 3, we propose the new design, including statisti-
cal models and the dose assignment rule. The simulation settings and results are presented in
Section 4. Finally, a discussion is given in Section 5.
The programs that were used to analyse the data can be obtained from
http://wileyonlinelibrary.com/journal/rss-datasets
2. Motivating trial
The aim of this paper is to propose a dose ﬁnding design for the LEVNEONAT clinical trial
based on the experiences from the ‘Neonatal seizures with medication off-patent’ trial (called
the ‘NEMO’ trial; NCT01434225 in www.ClinicalTrials.gov) (Pressler et al., 2015). The
NEMO trial is an open label phase I–II dose ﬁnding trial conducted between 2011 and 2013.
The objective of the trial was to ﬁnd the optimal dose of bumetanide that achieved themaximum
seizure reduction with an acceptable safety proﬁle out of four study doses (i.e. 0.05, 0.1, 0.2 and
0.3 mg kg−1). The primary efﬁcacy end point was deﬁned as the reduction of the electrographic
seizure burden by 80% or more within hours 3 and 4 after the ﬁrst bumetanide administration
compared with the baseline. The safety end point was binary and deﬁned as the occurrence of
a list of AEs within 48 h after the ﬁrst dose. The lowest acceptable efﬁcacy response rate was
50%, and the maximum tolerable toxicity rate was 10%. A phase I–II dose ﬁnding design with
dual binary efﬁcacy and safety end points was used (Zohar and O’Quigley, 2006). 14 evaluable
neonates were included in the trial. Four neonates were included at a dose of 0.05 mg kg−1,
three neonates at a dose of 0.1 mg kg−1, six neonates at a dose of 0.2 mg kg−1 and one at a dose
of 0.3 mg kg−1. During the trial, no major AE was observed according to the deﬁnition that
was speciﬁed in the protocol. However, after 14 neonates had been accrued, an unexpected AE
was observed: three neonates experienced hearing loss at different doses. These AEs might have
occurred during the treatment phase but could only be measured later by using a speciﬁc test
as babies could not express this AE earlier. Fig. 1 shows the estimated dose–efﬁcacy and the
dose–toxicity relationships with or without including hearing loss as an AE after the accrual
of 14 neonates. After including hearing loss as an AE, the model ﬁtted indicated that all doses
were unsafe, and thus the trial was terminated early following a recommendation by the Data
and Safety Monitoring Board.
Based on these results, a second trial, LEVNEONAT (registration number NCT 02229123 at
www.ClinicalTrials.gov) was planned for the same indication but with a different drug.
The aim of this new trial is to ﬁnd the optimal dose of levetiracetam out of the four doses 30,
40, 50 and 60 mg kg−1. Fig. 2 shows the dosing schedule and end point measurement scheme.
The loading dose is given at time 0, and after 4 h the efﬁcacy end point is evaluated. Between
hours 6 and 64, up to eight maintenance doses, deﬁned as a quarter of the loading dose, are
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Fig. 1. Estimated dose–efficacy and dose–toxicity relationships with or without hearing loss for the NEMO
clinical trial: , dose–response; , dose–toxicity without hearing loss; 4, dose–toxicity with hearing loss;
, minimum response target 50%; , maximal toxicity target 10%
time
Levetiracetam
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Fig. 2. LEVNEONAT clinical trial—doses and end point measurements scheme: the loading dose LD is
given at time 0 and after 4 h the efficacy end point is evaluated; up to eight maintenance doses (a quarter
of LD) are administrated between hours 6 and 64; the investigators have the option to add a second agent
A2 as a rescue medication; after 6 days, the first toxicity end point (short-term toxicity) is measured whereas
the long-term toxicity end point (i.e. hearing loss) is assessed after 30 days or when the neonate is released
from the hospital, whichever occurs first
administrated. After 6 days, the ﬁrst toxicity end point, which is referred to as the ‘short-term’
toxicity, is measured. The second toxicity end point (i.e. hearing loss), which is referred to as the
‘long-term’ toxicity, is assessed after 30 days or when the neonate is released from the hospital,
whichever occurs ﬁrst. During the treatment, the investigators have the option to add a second
agent A2 as a rescue medication when they believe that levetiracetam is not effective. The type
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of agent to be added is at the discretion of the investigator, with the possibility of reducing
the maintenance dose. In this trial, the investigators hoped that the dose ﬁnding method would
reﬂect the clinical practice as much as possible, including
(a) to account for not only efﬁcacy and short-term toxicity, as in the NEMO trial, but also
long-term toxicity (i.e. hearing loss) that cannot be measured earlier,
(b) to consider not only the loading dose but also the number (or quantity) of maintenance
doses of levetiracetam and
(c) to account for the fact that the second agent A2 might be added during the course of
treatment, and thus toxicity might be caused by levetiracetam, A2, or both.
Wehave considered two end points for toxicity rather than one combined end point for clinical
and logistical reasons rather than statistical. For instance, our twoAEdeﬁnitions differ for short-
term and long-term toxicities; then from a medical viewpoint the end points cannot be merged,
as we are interested in the estimation of each end point separately.Moreover, monitoring babies
during the ﬁrst 6 days of life for toxicity is already difﬁcult. If from day 6 to day 30 the second
outcome will not be observed there is no reason to require medical staff to undertake close
monitoring when it is not necessary.
The model that was proposed by Thall et al. (2014), which uses elicited numerical utilities for
the possible composite outcomes due to two efﬁcacy outcomes and one safety outcome, cannot
be adapted to this setting, since it does not take into account the timing of assessment of different
outcomes. Another three-outcome model was presented in Zhong et al. (2012), who proposed a
trivariate continual reassessment method (CRM) for a toxicity, efﬁcacy and a surrogate efﬁcacy
end point. But, even if changing the surrogate efﬁcacy with a surrogate toxicity, the assumption
of a surrogate end point is not suitable in this trial. The short-term toxicity is not a surrogate of
the long-term toxicity. Moreover, Thall et al. (2014) and Zhong et al. (2012) did not consider
adding a second agent during the course of treatment. Here, we model three end points and
propose the use of a pseudolikelihood approach for inference.
3. Methods
In this section, we describe three statistical models to describe the relationships between the
dose and efﬁcacy and short-term toxicity (denoted as T1) and long-term toxicity (denoted as
T2) respectively. These models will be used to guide the dose allocation and selection. The
correlation between efﬁcacy and toxicity was not taken into account since in previous studies
it was negligible. Let dk, dk ∈ .d1, d2, : : : , dK/, be the loading dose and d[i] be the dose that is
administered to the ith subject. Let yE,i be a binary efﬁcacy indicator that takes a value of 1 if the
ith subject experiences efﬁcacy and 0 otherwise, yT1,i be a binary short-term toxicity indicator
that takes a value of 1 if the ith subject experiences short-term toxicity T1 and 0 otherwise, and
yT2,i be a binary indicator for long-term toxicity T2.
3.1. Dose–efficacy model
Levetiracetam is administered through a loading dose dk, followed by a series of maintenance
doses, which are a quarter of the loading dose. As the efﬁcacy is evaluated before the adminis-
tration of the maintenance doses, it depends only on dk. Let pE.x/=P.yE,i =1|d[i] =x/ denote
the probability of efﬁcacy for a patient receiving dose x.Wemodel the dose–efﬁcacy relationship
by using a logistic model, as follows:
logit{pE.x/}=α1 + exp.β1/x, x∈{d˜1, : : : , d˜K}, .1/
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where α1 and β1 are intercept and slope parameters respectively, and d˜k is the ‘effective’ dose,
deﬁned as the prior estimate of efﬁcacy probability associatedwith dose dk (Zohar et al., 2013). It
is computed ﬁxing α1, β1 and pE and inverting equation (1). Research (Zohar et al., 2013; Yuan
et al., 2016) shows that using the effective dose rather than the actual dosage improves themodel
ﬁtting and estimation.We ﬁx the intercept at α1 =3, although other values can be used for other
applications (Lee and Cheung, 2009; Chevret, 1993). Shen and O’Quigley (1996) showed that
such a one-parameter model performs better than the two-parameter logistic model for dose
ﬁndingwith small samples. The coefﬁcient exp.β1/ is greater than 0 to ensure dosemonotonicity.
We assign β1 a normal prior with mean 0 and standard deviation 1.34 as suggested in Cheung
(2011), i.e. β1 ∼N.0, 1:34/, since we do not have any information to set a more informative prior
distribution.
3.2. Short-term toxicity model
The short-term toxicity T1 is assessed within 6 days from the initiation of the treatment. As
shown in Fig. 2, one challenge here is that, when clinicians believe that levetiracetam is not
adequately effective to reduce seizure, they may reduce or stop the maintenance dose and add a
new agent A2 to boost the treatment effect. This makes the modelling of T1 more complicated
than standard dose ﬁnding trials. The evaluation of toxicity of levetiracetam is confounded by
the possible addition ofA2 and affected by the number ofmaintenance doses that a baby actually
received. In other words, when toxicity is observed after adding A2, we do not know whether
that toxicity comes from levetiracetam, A2 or both. The second challenge is that, although
the assessment period for T1 is short (i.e. 6 days), new babies could arrive in hospitals at any
time and require immediate treatment. Thus, the so-called ‘late onset outcome’ problem may
occur, i.e. when a new baby arrives, some enrolled baby may not have completed the 6-day
toxicity evaluation, which hinders the adaptive decision of dose assignment for the new baby.
As noted by Liu et al. (2013) and Jin et al. (2014), whether there is a late onset outcome problem
depends on not only the length of the assessment period, but also on both the length of the
assessment period and the accrual rate. In the LEVNEONAT trial, the assessment period (i.e. 6
days) is shorter than in most trials but, as the accrual rate is fast, we may still face the late onset
outcome problem. We handle these two challenges in a uniﬁed framework using a weighted
pseudolikelihood approach.
We ﬁrst address the problem of potential late onset outcome. Let yi be yT1,i from now on.
After consulting the investigators, it appears that T1 is most likely to occur at the beginning of
the assessment period of 0–6 days; therefore, a modiﬁed time-to-event (TITE) CRM (Cheung
and Chappell, 2000; Braun, 2006) was developed to address the late onset toxicity problem. Let
Ti denote the time to toxicity of the ith patient and Tmax be the maximum length of the toxicity
assessment window for T1 (i.e. 6 days). Starting from the deﬁnition of a conditional distribution,
for tT , we obtain
P.Ti t|xi/=P.Ti t|xi, yi =1/P.yi =1|xi/,
where P.yi =1|xi/ is the probability of short-term toxicity for a patient receiving dose x, denoted
as pT1.x/. We model pT1.x/ by using a one-parameter logistic model as follows:
logit{pT1.x/}=α2 + exp.γ1/x, x∈{d¯1, : : : , d¯K},
where intercept α2 is ﬁxed, γ1 is the unknown slope parameter and d¯k is the effective dose
representing the prior estimates of the short-term toxicity for dose dk. As for efﬁcacy, this
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parameterization ensures that toxicity T1 monotonically increases with the dose; we assume a
normal prior γ1 ∼N.0, 1:34/ and α2 =3.
Let Tmax be the maximum assessment period, i.e. Tmax = 6 days. Taking a similar approach
to Braun (2006), we assume that the scaled time to toxicity t=Tmax follows a beta distribution
beta.1, ζ/. Thus, we have
P.Ti t|xi,Yi =1/=1−
(
1− t
Tmax
)ζ
, ζ >0:
We ﬁx the ﬁrst parameter of the beta distribution at 1 to decrease the complexity of the model
while still maintaining ﬂexibility for capturing various shapes of the time to toxicity. In addition,
as the sum of the two parameters of the beta distribution is greater than 1, it precludes the U-
shape of time to toxicity, which is unlikely in our application.
As the sample size is small and the number of toxicities that were observed in the trial is even
smaller, it is critical to choose an appropriate prior for ζ to avoid an extremely noisy estimate.
We elicit the prior distribution of ζ from clinicians as follows. We provide several different
distributions of time to toxicity to clinicians and ask them to pick the most likely one. Fig. 3
shows the distributions that we showed to our clinical collaborators. Distribution (b) was picked
as the most likely. We then assign ζ a gamma prior distribution with mean matched to that of
the distribution picked. For the LEVNEONAT trial, we set ζ ∼Ga.5, 1/ since the prior mean
of distribution (b) was 5. Fig. 3 shows also how the parameterized beta distribution can capture
various shapes where toxicity is supposed to occur at the beginning of the period. However, if
the posterior estimate of ζ is less than 1, this shape is reﬂected and toxicity occurs more likely at
the end of the period. For the LEVNEONAT clinical trial ζ was considered to be the same for all
doses, to avoid model complexity. Nevertheless, from the monotonicity assumption, the higher
is the dose, the earlier that toxicity occurs, and ζ could then depend on the dose by setting ζi =zλk ,
where λ<0 and zk is a transformed value of dk constrained to the interval [0, 1] (Braun, 2006).
Next,wediscuss how tohandle the confounding issuedue to thepossible additionof newagent
A2 during the course of administration of maintenance doses. The difﬁculty is that, if toxicity
is observed after A2 has been added, it is not clear that the toxicity is caused by levetiracetam,
A2 or both. We tackle this issue by creating a pseudo-observation yÅi to represent how likely the
toxicity is attributable tomaintenance doses. Speciﬁcally, let ni denote the number of times that a
maintenance dose has been administered to the ith patient, and let xi,m denote the actual dosage
of the maintenance dose (or the actual dosage of the loading dose, since there is a one-to-one
relationship). Given the actually observed toxicity outcome yi, we deﬁne a pseudo-observation
yÅi =w.ni, xi,m/yi
with weight
w.ni, xi,m/=
{
fw.ni, xi,m/τ , if A2 is added,
1, otherwise,
.2/
where fw.ni,xi,m/ is a prespeciﬁed function, and the constant τ < 1 represents the likelihood
that the toxicity is due to levetiracetam when all maintenance doses are given. The value of
τ should be elicited from clinicians. Basically, equation (2) says that, if A2 is not added, the
observed outcome yi should receive a full weight of 1 because the toxicity is fully attributable
to levetiracetam; however, if A2 is added during the treatment, only a fraction of toxicity, i.e.
fw.ni,xi,m/τ , should be attributable to levetiracetam.A similar approach has been used byYuan
et al. (2007) to handle different grades of toxicity. We suggest use of the function
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Fig. 3. Four elicited plots, showing several beta distributions, were given to investigators for the LEV-
NEONAT clinical trial (in particular, plot (b) was selected): (a) ζ D3I (b) ζ D5I (c) ζ D7I (d) ζ D9
fw.ni, xi,m/= exp.γnixi,m/−1exp.γNMxK/−1 ,
where NM is the maximum number of maintenance doses deﬁned in the protocol, xK is the
dosage of the last dose level and γ is a calibration parameter. This function ensures that the
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(a)
(c)
(b)
Fig. 4. Values of fw for several doses (, 30 mg kg1; 4, 40 mg kg1; C, 50 mg kg1; , 60 mg kg1)
versus the number of maintenance doses and for three γ-values: (a) γ D2104; (b) γ D0.002; (c) γ D0.02
likelihood of toxicity that is attributable to levetiracetam increases with the total accumulative
maintenance doses that a baby has received. When A2 is added and there are no maintenance
doses, fw.ni =0,xi,m/=0, and thus yÅi =0 since in this case toxicity is attributable mainly to A2;
when all maintenance doses are administered at the maximum dose, fw.ni =NM,xi,m =xK/=1,
and thus yÅi =τyi. In the LEVNEONAT trial, on the basis of previous studies and consultation
with clinicians, τ was set to 0.8 with γ =0:002. Ideally, τ and γ should be estimated from data;
however, they are not identiﬁable because of complete confounding between levetiracetam and
A2. Thus, we use sensitivity analysis as a tool to examine the performance and robustness of
the values of τ and γ. In Fig. 4, possible choices of γ and the behaviours of fw for our four
doses are shown. Increasing γ pushes weights down to 0 except for the last maintenance doses,
whereas decreasing γ leads to more linear weights. The proposed form of fw gives weight 0 to
toxicity if no maintenance doses are given; if the investigators prefer to give a weight greater
than 0 in this situation, a variant, such as
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w.ni,xi,m/=
{
τL +fw.ni, xi,m/.τ − τL/, if A2 is added,
1, otherwise,
can be used, where τL represents the value to give at the loading dose (the same to all doses for
simplicity). An alternative idea, which is not developed in this paper, consists of eliciting each
weight directly from clinicians.
Putting all together, given n babies treated in the trials, the pseudolikelihood for T1 is given
by
QL1.γ1|y,α1, ζ/∝
n∏
i=1
[{
1−
(
1− ui
Tmax
)ζ}
pT1
]yÅi [
1−
{
1−
(
1− ui
Tmax
)ζ}
pT1
]1−yÅi
: .3/
We used pseudolikelihood in a general sense that the likelihood that is yielded by equation
(3) is not necessarily the true likelihood because we attached an empirical weight to toxicity
probability pT1. In the special case that the time to toxicity follows a uniform distribution,
equation (3) leads to the true likelihood. Without considering the weight, yÅ actually follows
the quasi-Bernoulli likelihood (Gourieroux et al., 1984; McCullagh and Nelder, 1989). Because
of the weights, it is more appropriate to be called pseudolikelihood as explained.
3.3. Long-term toxicity model
Unlike short-term toxicity T1, which can be observed any time between day 1 and 6, long-term
toxicity T2 (i.e. hearing loss) is evaluable only at day 30, although it may occur long before day
30; see Fig. 2. As T1 is potentially predictive of T2, let pT2.x,yT1/=P.yT2 =1|x,yT1/; we model
T2 by using the logistic model
logit{pT2.x, yT1/}=α3 + exp.δ1/x+ exp.δ2/yT1, x∈{d˙1, : : : , d˙K}, .4/
where {d˙1, : : : , d˙K} are effective doses standing for the prior estimates of toxicity probability
of T2 at each dose, α3 is ﬁxed and δ1 and δ2 are parameters to be estimated. Because both
exp.δ1/ and exp.δ2/ are greater than 0, a patient is more likely to experience T2 if he or she has
experienced short-term toxicity T1 or/and received a high dose. We do not use a TITE model
for T2 because T2 cannot be observed in realtime and can be measured only at day 30. Similarly
to T1, the measurement of T2 is also confounded by the potential addition of A2. We use
the same pseudo-observation approach to handle that issue by replacing the actually observed
toxicity outcome yT2 with yÅT2 =w.nm, xm/yT2, wherew.nm,xm/ is provided by equation (2). For
coherence, we replace yT1 in equation (4) with yÅT1; the same value as used in the model for T1.
Let nÅ be the number of patients who have already completed the assessment of T2; the
resulting pseudolikelihood can then be written as
QL2.·/=
nÅ∏
i=1
pT2.x[i], y
Å
T1,i/
yÅT2, i{1−pT2.x[i],yÅT1,i/}1−y
Å
T2, i :
Prior distributions for δ1 and δ2 are N.0, 1:34/ and α3 = 3. Model (4) deﬁnes the conditional
distribution of yT2 given yT1; the marginal probability of yT2, which is denoted as pT2, can be
computed by using the law of total probability.
3.4. Avoiding stickiness
It has been documented that early unexpected short-term toxicity outcomes have a strong in-
ﬂuence on the dose allocation process when the target probability is included in the distribution
tails. Moreover, it is well known in sequential decision making that a ‘greedy’ algorithm can
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become stuck at a suboptimal action because it repeatedly takes the suboptimal action; it fails
to take and thus to obtain enough data on an optimal action. This has been recognized also in
the context of dose ﬁnding clinical trials (Azriel et al., 2011; Thall and Nguyen, 2012; Oron and
Hoff, 2013; Yuan et al., 2016). In particular, this stickiness property leads to the allocation of
many patients at lower doses for a long period before starting the escalation. Thus, following
the approach of Resche-Rigon et al. (2008, 2010), we weight the pseudolikelihood that was
described above for T1 (3) with wri.·/, which are called relevance weights from now on, which
are adaptive weights depending on the number of patients already accrued in the trial and on
the number of short-term toxicities already counted at each dose. Let nalloc,dk be the current
number of patients allocated at dose k and nDLT,dk be the current number of patients who ex-
perienced toxicity at dose k. Regarding the LEVNEONAT clinical trial, we have developed a
speciﬁc scheme as follows:
wri.yi,di/=
⎧⎨
⎩
1, if yi =0,
min
[
max
{
π
nalloc,di
nmax
+ .1−π/nDLT,di
nalloc,di
,
nalloc,di
nmax
}
, 1
]
, if yi =1,
where nmax is a constant, which is usually linked to the target probability, and π is a mixture
constant containing the percentage of patientswhowere allocated at dose i and to the percentage
of toxicity seen at dose i. After nmax patients have been allocated at each dose, all the weights
are equal to 1. Fig. 5 shows the three-dimensional plot of this function in the case nmax =
20 and π = 0:5, which are constants based on sensitivity analysis. Therefore, a ﬁnal weighted
pseudolikelihood was proposed as follows:
QL1.γ1|y,α1, ζ/=
n∏
i=1
[{
1−
(
1− ui
Tmax
)ζ}
pT1
]wriyÅi [
1−
{
1−
(
1− ui
Tmax
)ζ}
pT1
]wri.1−yÅi /
:
Wedecided to apply thisweight schemeonly onT1 since it has themost inﬂuence at the beginning
of the trial as shown in the next section. Moreover, toxicity in the long term, e.g. hearing loss,
is more dangerous, and therefore we would not downgrade this toxicity value.
3.5. Dose allocation rule
To ensure that the trial is ethically acceptable, constraints on both safety and efﬁcacy were
imposed. At the inclusion of each new cohort, the aim is to assign to the patient(s) the most
effective dose that is also sufﬁciently safe but, if all the doses are too toxic or not sufﬁciently
efﬁcient, the trial must be stopped.
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After n neonates have been enrolled, of whom n2, n2n, had ﬁnished the entire follow-up
until the assessment of T2, the dose for the next cohort of neonates is selected from the set
of acceptable doses deﬁned as the doses verifying the following set of conditions, where the
probabilities are computed using the current parameter estimates:
(a) P.pT1 > τT1 + 
1/<g.n/,
(b) P.pT2 > τT2 + 
2/<g.n2/1n2>1 and
(c) P.pE < τE − 
E/<g2.n/1n>11 ,
where 
1, 
2 and 
E are speciﬁed constants as discussed below.
Finally, the highest efﬁcient dose under toxicity constraints is selected. 1.:::/ refers to the
indicator function, which assumes a value of 1 when the condition in the subscript holds and
0 otherwise. In this way T2 and efﬁcacy constraints inﬂuence the dose escalation only when
available. Adaptive choices of the thresholds, g.n/ and g2.n/, are proposed depending on the
number of patients who were already enrolled in the trial for which we have data:
g.n/=max
(
0:5, 0:9
1
1+0:025n
)
,
g2.n/=max
(
0:5, 0:9
1
1+0:02n
)
:
The errors 
E, 
1 and 
2 were set equal to 0:02, based on a sensitivity analysis, and in LEV-
NEONAT clinical trial τT1 = τT2 = 0:1 and τE = 0:6. In the case of no eligible dose, because
the minimum effective dose is a dose that is higher than the maximum tolerated dose, the trial
is stopped. Furthermore, the trial is stopped if P.pT1 > τT1|d1/> 0:9, P.pT2 > τT2|d1/> 0:9 or
P.pE < τE|dK/>0:9, i.e. if the ﬁrst dose is too toxic or the last dose is not sufﬁciently efﬁcient,
similarly to what is proposed in Thall and Cook (2004). The no-skipping rule is applied, i.e. a
dose level can be assigned only if at least one patient is allocated to all lower doses.
At the end of the trial, the minimum effective dose is computed as
de, min =argmin
d∈D
|pˆE.d/− τe|
and the maximum tolerated dose as
dt, max =min.argmin
d∈D
|pˆT1.d/− τp1|, argmin
d∈D
|pˆT1.d/− τp2|/:
The dose that is recommended at the end is equal to dt, max if de, mindt, max and none otherwise.
The pˆE.d/, pˆT1 and pˆT1.d/ are deﬁned as the posteriormedian values of those probabilities given
the dose d.
4. Evaluation of the method proposed
4.1. Simulation setting
The performance of the trial design proposed was evaluated through six scenarios (additional
scenarios are given in the Web appendix A). For each scenario, 1000 phase I–II trials were sim-
ulated. A cohort of two newborns per dose and a sample size of 30, 40 and 50 neonates were set
for each trial, assuming an accrual rate of one newborn per 15 days. The skeletons were elicited
by LEVNEONAT investigators, and were pE = .0:5, 0:6, 0:7, 0:8/, pT1 = .0:005, 0:05, 0:1, 0:2/
and pT2 = .0:001, 0:01, 0:05, 0:1/ for efﬁcacy, short-term toxicity and long-term toxicity respec-
tively. The investigators were asked to give their estimates of those probabilities and then to
reach a consensus. Therefore, these skeletons are the consensus results, and we used them in all
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Table 1. Results for the first three scenarios in terms of correct dose selection for sample
sizes of 30, 40 and 50 neonates†
Results for the following doses: PCSs for the following sample sizes:
1 2 3 4 30 40 50
Scenario 1 (recommended dose 3)
pT1,true 0.001 0.01 0.1 0.2 M1 0.673 M1 0.737 M1 0.798
pT2,true 0.001 0.01 0.1 0.2 M2 0.582 M2 0.685 M2 0.766
pE,true 0.6 0.7 0.8 0.9
pa 0 0 0 0
Scenario 2 (recommended dose 3)
pT1,true 0.001 0.01 0.1 0.2 M1 0.641 M1 0.742 M1 0.788
pT2,true 0.001 0.01 0.1 0.2 M2 0.53 M2 0.657 M2 0.717
pE,true 0.6 0.7 0.8 0.9
pa 0.5 0.5 0.5 0.5
pT1|A2,true 0.005 0.05 0.15 0.25
pT2|A2,true 0.005 0.05 0.15 0.25
Scenario 3 (recommended dose 4)
pT1,true 0.001 0.001 0.01 0.1 M1 0.8 M1 0.839 M1 0.871
pT2,true 0.001 0.006 0.026 0.09 M2 0.698 M2 0.742 M2 0.781
pE,true 0.5 0.6 0.7 0.8
pa 0.5 0.5 0.5 0.5
pT1|A2,true 0.005 0.005 0.05 0.15
pT2|A2,true 0.005 0.005 0.05 0.15
†In the second to ﬁfth columns, values for pT1, pT2 and pE along with pa, pT1|A2 and
pT2|A2 used in simulations are summarized for each dose. In the sixth to eighth columns, the
percentages of correct selection, PCS, are given.
simulations.We did not change them since they come from clinical relevance; however, we tested
them in several scenarios, i.e. we changed the position of the true dose to be selected. The time
to toxicity was simulated from an exponential distribution with rate 1=40 h−1, and the number
of maintenance doses follows a beta–binomial distribution with a= 7 and b= 6 to be close to
the total number of maintenance doses. This action reﬂects the physicians’ behaviour of trying
to administer all maintenance doses. For simplicity, A2 was considered added after the efﬁcacy
evaluation, if it was added. The target probabilities that were chosen for simulations were those
speciﬁed in the LEVNEONAT protocol, i.e. τT1 = τT2 =0:1 and τE =0:6.
Scenarios for the simulation study were generated under four-level marginal efﬁcacy, short-
term toxicity and long-term toxicity probabilities, which were not based on the design’s model
or any other model. For efﬁcacy observations, the true probabilities were speciﬁed by the vector
pE,true. Then, a logit–normal distribution was chosen, with standard deviation equal to 0.6
and mean computed according to each scenario, and then discretized. In case of an ineffective
dose, A2 was added with probability pa. Scenarios in which A2 increases the probabilities of
toxicities and scenarios where they remain unchanged were tested. T1 outcomes were drawn
from a Bernoulli distribution and depended on A2. In this case, two vectors of probabilities
were set: pT1,true and pT1|A2,true, with or without A2 respectively. In a similar way, T2 was
obtained from a Bernoulli distribution and depended on both T1 and A2. Three vectors of
probabilities were decided:
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(a) pT2|Y1=0,true for the probability of T2 without T1,
(b) pT2|Y1=1,true for the probability of T2 along with T1 and
(c) pT2|A2,true, for the probability of T2 when A2 is added.
For simplicity, only marginal probabilities pT2,true were reported, but all values can be found in
the Web Table 1 in the Web appendix A.
All the scenarios were simulated with (M1) or without relevance weights (M2) associated
with the pseudolikelihood scheme. The percentage of correct dose selection, PCS, at the end of
the trial, the number of neonates that experienced toxicities, ntox, and dose allocation percent-
ages were compared to evaluate our design proposition performance. The posterior quantities
were computed by using Hamiltonian Monte Carlo sampling, using Rstan version 2.6.0 (Stan
Development Team, 2016).
4.2. Results
Results are shown inTables 1 and2.More results in termsof thenumberofnewborns that showed
toxicity, ntox, and dose allocation over the entire trial are given in the Web-based supporting
materials appendix A. In scenario 1, where A2 was not added, M1 had high PCS compared
with M2 on the basis of 30 patients and more, above 67%. This simple setting evaluates the
Table 2. Results for the last three scenarios in terms of the correct dose selection for
sample sizes of 30, 40 and 50 neonates†
Results for the following doses: PCSs for the following sample sizes:
1 2 3 4 30 40 50
Scenario 4 (recommended dose 4)
pT1,true 0.001 0.005 0.01 0.05 M1 0.841 M1 0.821 M1 0.804
pT2,true 0.001 0.007 0.015 0.05 M2 0.766 M2 0.746 M2 0.722
pE,true 0.3 0.4 0.5 0.6
pa 0.5 0.5 0.5 0.5
pT1|A2,true 0.005 0.009 0.012 0.06
pT2|A2,true 0.005 0.009 0.012 0.06
Scenario 5 (recommended dose 2)
pT1,true 0.01 0.1 0.25 0.35 M1 0.619 M1 0.706 M1 0.768
pT2,true 0.009 0.1 0.18 0.26 M2 0.623 M2 0.647 M2 0.68
pE,true 0.6 0.7 0.8 0.9
pa 0.5 0.5 0.5 0.5
pT1|A2,true 0.01 0.1 0.25 0.35
pT2|A2,true 0.01 0.1 0.25 0.35
Scenario 6 (recommended dose 2)
pT1,true 0.001 0.01 0.1 0.2 M1 0.623 M1 0.682 M1 0.713
pT2,true 0.01 0.1 0.2 0.3 M2 0.623 M2 0.663 M2 0.689
pE,true 0.6 0.7 0.8 0.9
pa 0.5 0.5 0.5 0.5
pT1|A2,true 0.005 0.05 0.15 0.25
pT2|A2,true 0.005 0.05 0.15 0.25
†In the second to ﬁfth columns, values for pT1, pT2 and pE along with pa, pT1|A2 and
pT2|A2 used in simulations are summarized for each dose. In the sixth to eighth columns, the
percentages of correct selection, PCS, are given.
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inﬂuence of relevance weights, i.e. M1 versus M2. Scenario 2 was similar to scenario 1 but with
the administration of A2 associated with pa = 0:5. In this setting, the PCSs were higher than
in scenario 1, as A2 allowed a better estimation of T1 and T2, keeping a similar amount of
observed ntox across trials (Table 1 in the Web appendix A). Again, PCS by using M1 exceeds
that by using M2. In scenario 3, the optimal dose under toxicity restrictions was the last of the
panel, and A2 was added; the PCS obtained was above 80% by using M1. A higher difference
in PCS was observed, compared with scenarios 1 and 2, between M1 and M2.
In scenario 4, all doses were safe but only the last was considered efﬁcacious regarding the
target of 60%. In this case, the PCSs were above 71% for all sample sizes and regarding M1 and
M2. Scenario 5 was selected to evaluate a situation where the probabilities of T1 remain the
same whereas it increases for T2 when adding A2. The PCSs obtained were higher for M2 for
sample sizes of 30. In scenario 6 the T1 and T2 were simulated independently from each other.
The observed PCS, in this case, was around 60% for all sample sizes and regarding M1 and M2.
In the Web appendix A, two additional scenarios are given (7—too toxic—and 8—not efﬁ-
cient) that evaluate the efﬁciency of our proposed stopping rules. In these cases, stopping was
recommended in 90% on average of cases where all doses were too toxic and in 94% on average
of cases where all the doses were not efﬁcient.
In the Web appendix B, we compared the performance of a modiﬁcation of the TITE CRM
when combining the two toxicities in only one variable, YT. We ran simulations in six scenarios,
which was considered important to see differences between our method and the modiﬁed TITE
CRM method (referred as Mtitecrm). This simpler method tends to overdosing patients and the
PSCs are lower, above all for small sample sizes.
5. Discussion
The objective of our work was to propose a dose ﬁnding method for trials in paediatrics and,
more speciﬁcally, in neonate populations when delayed toxicities are observed such as in the
LEVNEONAT trial. To date, such approaches have been rare in the literature. Indeed, there
are fewer clinical trials in neonates, and therefore only a few methods have been proposed or
adapted for this vulnerable population. Recently, the European Medicines Agency and Food
and Drug Administration have proposed a modiﬁcation of the ‘Guidance for Industry: E11
clinical investigation of medicinal products in the paediatric population’ where the need for
better designs and methods for paediatrics was pointed out. In this work, we have speciﬁcally
taken into account in our models the real practical issues that prevent us from using other
methods that have been proposed for adults. In general, this design could be also used for the
evaluation of other drugs treating seizures in neonates, on one hand, or other diseases where
toxicities are correlated and a rescue agent is used when one treatment does not work, on the
other hand. The models that are presented are very ﬂexible and can be easily adapted to other
situations. For example, it is possible to include the scaled time-to-toxicity part, which here was
parameterized as a beta distribution, also in the long-term toxicity model to take care of late
onset toxicity. The weights that are used for creating the pseudo-observations and the relevance
weights can be customized according to prior knowledge on the toxicity and efﬁcacy of the
drug. Then, since in our proposed method the two toxicities are estimated in a joint likelihood,
it is very easy to add a new constraint on the probability than at least one of the two types
of toxicity is lower than the unacceptable threshold. Indeed, the formula can be written as
P.Y1 =1∪Y2 =1/=pT1 +pT2|Y1=0.1−pT1/:
In the LEVNEONAT trial, the dose allocation scheme and the efﬁcacy and toxicity outcomes
of this trial were more complex than in usual dose ﬁnding studies. The resulting proposed
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method was based on the modelling of efﬁcacy, short-term and long-term toxicities taking
into account the number of maintenance doses and a second agent that was highly correlated
to a failure outcome. The model was built with the collaboration of investigators and other
collaborators who were involved in this trial to develop the best model to answer the clinical
question and practice constraints. We modelled T2 conditionally on T1 since we followed the
physicians’ knowledge and experience. We tested this hypothesis by adding scenarios where T1
is not predictive for T2, and we found that the model could still achieve proper estimates. A
beta distribution was used for the TITE part in the T1 model again after discussing with the
investigators.Wedid not test the casewhere toxicities appearmore at the endof the observational
window, but our parameter ζ is free to take values for which the beta shape is inverted. A richer
andmore complicatedmodel couldhavebeenproposed;however, the small sample size, the small
toxicity targets and the constraints on data acquisition led to simplifying some of its aspects.
For example, the model does not take into account the correlation between efﬁcacy and toxicity.
We decided not to complicate the model since in previous studies the correlation was negligible.
However, working with marginal distributions, we do not expect that adding correlation in the
model should change the results much (Cunanan and Koopmeiners, 2014). Nevertheless, our
proposition was sufﬁciently richer to reﬂect the complexity of this dose ﬁnding clinical trial.
Whenmodelling, there should be a balance between simplicity and the right complicated way to
represent clinical considerations and that, when information is available, it should be introduced
in the design. Then, this method has the advantage of being easily customized, depending on
the application, and this is the reason for the ad hoc choices.
In general, the simulation study showed that the model proposed could be a good trade-off
between a high PCS and a reasonable number of observed short- and long-term toxicities under
small sample constraints. The clinical relevance weights made it possible to avoid becoming
stuck during the dose allocation process. Moreover, the model was shown to be robust, i.e. the
PCS was less sensitive to sample size. Scenarios were selected to test several possible situations.
The probability of adding A2 was set at 50% and not more since we believe that it is useless to
perform a clinical trial where most of the neonates received other competing drugs. All ﬁxed
parameters were chosen using ﬁrst investigators’ advice and then testing them in a sensitivity
analysis.After theNEMOexperience, we took care inmodellingT2, and also physicians selected
the new drug better. The ﬁrst inclusion in the LEVNEONAT trial took place in September
2017.
In conclusion, this design was the result of a successful and close collaboration across statis-
ticians, physicians and other trial collaborators. In the last 20 years, many dose ﬁnding designs
have been proposed in the oncology setting and almost none for paediatrics. There is a crucial
need for efﬁcient designs in this population, and this paper is an example of how and what can
be done. Outcomes that cannot be measured in realtime, such as hearing loss, and the adding of
rescue medications are very common features in paediatrics trials and this design can be easily
customized for them.
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